To the best of our knowledge, this is the first report demonstrating that β-ARs are invariably expressed in different types of human sarcomas and provides a rationale for the utilization of the non-selective β-AR antagonist propranolol to enhance the response to standard chemotherapy. The gene discussed is ADRB2; the disease is sarcoma.